Company Overview of The Translational Genomics Research Institute
The Translational Genomics Research Institute develops earlier diagnostics and treatments. It develops diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes, and other complex diseases. The company also provides bio4d to offer tools for managing various aspects of the biospecimen lifecycle, including related data enabling clinical genomics data warehouse capabilities for data mining and integrative analysis for the discovery or validation of biomarkers, diagnostics, and therapeutics. In addition, The Translational Genomics Research Institute offers genome technology and core services; genome technology for performing contemporary genetic analysis to benefit the...
445 North Fifth Street
Phoenix, AZ 85004
Founded in 2002
Key Executives for The Translational Genomics Research Institute
Founder, President, Research Director and Director
Vice President of Finance
Chief Operating Officer and President of TGen Health Ventures
President of TGen Foundation
Executive Vice President and Physician-In-Chief
Compensation as of Fiscal Year 2014.
The Translational Genomics Research Institute Key Developments
Spectrum Health Collaborates with Dell and Translational Genomics Research Institute to Expand International Pediatric Cancer Research to Lebanon
Mar 18 15
Spectrum Health announced its engagement in international pediatric cancer research. Together with Helen DeVos Children's Hospital, Dell and the Translational Genomics Research Institute, Spectrum Health will bring a personalized medicine clinical trial to children fighting pediatric cancers in Lebanon. Led by Giselle Sholler, MD, MSC, director of pediatric oncology research, Helen DeVos Children's Hospital and Jeffery Trent, PhD, FACMG, president and research director, TGen, the trial focuses on identifying drug treatments tailored, or personalized, to the specific genomic changes within the tumors of children with aggressive cancers. Also referred to as precision medicine, this type of research aims to customize drug treatment plans to the unique genetic makeup of an individual's tumor cell. Highly advanced computations provide explicitly detailed genomic information. In the trial, researchers study tumor biopsies using DNA and RNA sequencing performed at TGen. The data is then shared with Spectrum Health and analyzed using Dell computer power and complex algorithms constructed by the research team. An international group of physicians and researchers collaborate on the findings - through a customized online virtual meeting space - and design recommended treatment plans targeted for each patient's tumor. Ray Saab, MD, pediatric oncologist, American University of Beirut, Lebanon, is the physician investigator for the Lebanon arm of the NMTRC precision medicine trial.
the Translational Genomics Research Institute and Ceres Nanosciences, Inc. Collaboration to Develop High-Throughput Nanotrap Enrichment Methods for Mass Spectrometry
Jul 10 14
The Translational Genomics Research Institute and Ceres Nanosciences Inc. announced a development collaboration to benefit patients with cancer, infectious diseases, and other life-threatening illnesses. TGen to uncover the underlying molecular causes of disease, as well as developing automated workflows to enable molecular medicine. Ceres, a biotechnology company located in northern Virginia, has developed and commercialized a novel nanotechnology, the "Nanotrap", which provides powerful sample processing capabilities for a wide array of diagnostic applications and sample handling needs. The Nanotrap technology was invented at George Mason University (Mason) under funding from the National Institutes of Health (NIH) for biomarker discovery applications, and currently is being developed into commercial grade products by Ceres with continuing support from NIH, Defense Advanced Research Projects Agency, Department of Homeland Security (DHS), and the Commonwealth of Virginia. The combination of Ceres' Nanotrap technology and TGen's world-class research capabilities and resources will lead to significant improvements in high sensitivity and high throughput clinical diagnostics, providing substantial patient benefit with newer, more accurate, and more reliable testing methods for a range of life-threatening diseases. Ceres, TGen and Mason will use the exciting preliminary results to seek additional collaborations and support to develop an array of new sample processing and diagnostic solutions.
The Translational Genomics Research Institute and Easton-Bell Sports, Inc Announce Partnership for Biomarker Study of Concussive Injuries
May 14 13
The Translational Genomics Research Institute (TGen), and Easton-Bell Sports, Inc. through its Riddell brand, announced they would work together on a study designed to advance athlete concussion detection and treatment. Information gathered through the study will also be used to develop new football headgear and further refine updates to player monitoring technology. The genesis of this potentially study is to merge a player's genetic information with real-time microelectronic information captured by Riddell's Sideline Response System (SRS). A highly sophisticated, data-intensive system, Riddell SRS provides researchers, athletic staff and players with a wide range of valuable information on the number and severity of head impacts a player receives during games and practices. Employed since 2003 by several well-respected research institutions, Riddell SRS has captured 1.8 million impacts from youth to elite football competition, and its data has led to impactful changes to rules, how the game is played and coached, and has informed new helmet designs. While the joint study will begin with football, the Riddell-TGen partnership has the potential to improve sports equipment manufactured by brands in the broader Easton-Bell Sports portfolio, including headgear for hockey, baseball, cycling, snowsports, and powersports. As part of the study, TGen will work with the Barrow Neurological Institute whose B.R.A.I.N.S. (Barrow Resource for Acquired Injury to the Nervous System) program treats patients who have sustained a traumatic brain or spinal cord injury.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|